首页> The Journal of clinical investigation> Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.

导出 OA

翻译打印收藏纠错

第一作者： Peter,Zanvit

第一单位： Early Oncology Research.

作者： Peter,Zanvit ^[1] ; Dewald,van Dyk ^[2] ; Christine,Fazenbaker ^[1] ; Kelly,McGlinchey ^[1] ; Weichuan,Luo ^[1] ; Jessica M,Pezold ^[1] ; John,Meekin ^[1] ; Chien-Ying,Chang ^[2] ; Rosa A,Carrasco ^[1] ; Shannon,Breen ^[1] ; Crystal Sao-Fong,Cheung ^[2] ; Ariel,Endlich-Frazier ^[2] ; Benjamin,Clark ^[2] ; Nina J,Chu ^[1] ; Alessio,Vantellini ^[3] ; Philip L,Martin ^[4] ; Clare E,Hoover ^[5] ; Kenesha,Riley ^[5] ; Steve M,Sweet ^[4] ; David,Chain ^[4] ; Yeoun Jin,Kim ^[4] ; Eric,Tu ^[4] ; Nathalie,Harder ^[6] ; Sandrina,Phipps ^[2] ; Melissa,Damschroder ^[2] ; Ryan N,Gilbreth ^[2] ; Mark,Cobbold ^[1] ; Gordon,Moody ^[1] ; Emily E,Bosco ^[1]

作者单位： Early Oncology Research. ^[1] Biologics Engineering. ^[2] Discovery Sciences, Oncology R&D, and. ^[3] Oncology Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA. ^[4] Clinical Pathology Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom. ^[5] Computational Pathology, AstraZeneca, Munich, Germany. ^[6]

关键词 Oncology Prostate cancer